Bertrand Parmentier, CEO of the Pierre Fabre Laboratories

Facing contrasted results of its two divisions, the Pierre Fabre Laboratories are cutting more than 550 jobs in the pharmaceutical division with the aim to restore and boost its competitiveness. In parallel, the new strategic plan, entitled "Trajectoire 2018", aims at accelerating the international growth of the dermo-cosmetics division, in particular through a development strategy focused on its current brand portfolio, particularly in Asia where the Avène brand is already very successful, and in the US with the launch of Hemangeol, an innovative treatment in the field of pediatric dermatology.

While the dermo-cosmetics division, which represents 55% of sales, has seen sustained growth, providing most of the group’s profits, the pharmaceuticals division has become very fragile due to the double effect of low R&D productivity and a major loss of revenues in France.

Through the expected restoration of economic balance between the two divisions and the accelerated international growth, Trajectoire 2018 aims to put the Pierre Fabre group in a financial position to acquire new products, with the priority of strengthening its pharmaceuticals activities.

"Trajectoire 2018 is a corporate project that forms a renewed vision of the ‘From Health to Beauty’ continuum of activities that makes us stand out from the rest of the healthcare industry. Focused on innovation, international development and the creation of sustainable value, it is a project which aims to reinvent the company in a spirit of solidarity, in line with its values, and to allow its on - going development from its home territory," emphasised Bertrand Parmentier, CEO of the Pierre Fabre Laboratories.